Drug Profile
Tocilizumab biosimilar - Qyuns Therapeutics
Alternative Names: QX-003SLatest Information Update: 15 Feb 2023
Price :
$50
*
At a glance
- Originator Qyuns Therapeutics
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 14 Feb 2023 Phase-II clinical trials in Rheumatoid arthritis in China (IV) (Qyuns Therapeutics pipeline, February 2023)
- 01 Dec 2021 Qyuns Therapeutics completes a phase-I trial in Rheumatoid arthritis (In volunteers) in China (IV) (ChiCTR1900021808)
- 11 Mar 2019 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (IV) (ChiCTR1900021808)